Fox Chase’s Hossein Borghaei Honored as Lung Cancer Heroes Award Winner

Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center.
Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center.

PHILADELPHIA (October 6, 2021)—Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, has been named one of three winners of the second annual Lung Cancer Heroes awards program.

Borghaei, who is a co-leader of the Molecular Therapeutics Program at Fox Chase and an authority in the field of lung cancer immunotherapy, was recognized for his national and international service to the lung cancer community.

“I am greatly honored to receive this award, which recognizes all the patient care and cutting-edge research that takes place at Fox Chase Cancer Center,” he said.

Borghaei, who is also the Gloria and Edmund M. Dunn Chair in Thoracic Surgical Oncology at Fox Chase, has led numerous investigator-initiated trials and was the first author to publish on the role of immunotherapy in non-small cell lung cancer in the New England Journal of Medicine.

The award is bestowed by CURE Media Group—a multimedia platform devoted to cancer updates, research, and education that reaches over one million patients, survivors, and caregivers—in partnership with Takeda Oncology.

“We are so excited to recognize the three winners of this year’s Lung Cancer Heroes program. With help from our friends at Takeda, I am honored to present this year’s winners. Each of these individuals exemplifies everything that a hero is to us, someone who has had a profoundly positive impact on the lives of patients with lung cancer,” said Mike Hennessy Jr., president and CEO of MJH Life Science, parent company of CURE Media Group.

“Takeda is honored to partner with CURE and the patient advocacy community to sponsor the Lung Cancer Heroes program again this year,” said Fatima Scipione, head of patient advocacy and engagement at Takeda Oncology.

“We are inspired by the work and dedication of the Lung Cancer Heroes being recognized. Together, we are committed to advancing research and leveraging science to improve the lives of people living with lung cancer.”

The Lung Cancer Heroes celebration will take place virtually on Thursday, October 28, 2021, from 6:30 p.m. to 8:30 p.m. EST. The event is sponsored by Takeda in partnership with Lung Force, the GO2 Foundation for Lung Cancer, LUNGevity, the Lung Cancer Foundation of America, and the Lung Cancer Research Foundation.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427